MajesTEC-9: Teclistamab significantly improves PFS and OS versus standard therapies in patients with RRMM

CHICAGO 2026

Multiple Myeloma (MM)

MajesTEC-9: Teclistamab significantly improves survival outcomes in patients with RRMM

ASH 2025

Multiple Myeloma (MM)

LBA-6: MajesTEC-3: Unprecedented outcomes reinforce teclistamab plus daratumumab as a potential new standard of care for RRMM

EHA 2026

Multiple Myeloma (MM)

MonumenTAL-3: Talquetamab-daratumumab regimens significantly improve PFS in patients with RRMM

EHA 2026

Multiple Myeloma (MM)

MajesTEC-3: Teclistamab plus daratumumab maintain improved PFS and MRD negativity across high-risk multiple myeloma populations

EHA 2026

Lymphoma

EPCORE DLBCL-1: Epcoritamab significantly improves PFS in patients with R/R LBCL

CHICAGO 2026

Multiple Myeloma (MM)

SUCCESSOR-2: Addition of mezigdomide to Kd improves PFS and response rates in patients with RRMM

CHICAGO 2026

Lung, Respiratory and Thoracic Cancer

LBA4: HARMONi-6: Ivonescimab plus chemotherapy significantly improved OS versus tislelizumab plus chemotherapy in previously untreated advanced squamous NSCLC

ESMO 2025

Breast Cancer

ASCENT-03: First-line sacituzumab govitecan improves PFS versus chemotherapy in patients with advanced TNBC ineligible for PD-1/PD-L1 inhibitors

Genitourinary Cancer

Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration

Lancet Oncol

Tang C, Sherry AD, Hwang H, Farris DP, Francolini G, Di Cataldo V, Livi L, Tran P, Corn PG, Aparicio A, Simontacchi G, Kiess AP, Wang JH, Fonteyne V, Bultijnck R, Phillips R, Deek MP, Olson R, Harrow S, Marvaso G, Lorubbio C, Jereczek-Fossa BA, Ludmir EB, Blanchard P, Warner A, Sun R, Palma DA, Ost P

doi: 10.1016/S1470-2045(25)00658-8

Related content

MajesTEC-9: Teclistamab significantly improves survival outcomes in patients with RRMM

LBA-6: MajesTEC-3: Unprecedented outcomes reinforce teclistamab plus daratumumab as a potential new standard of care for RRMM

MonumenTAL-3: Talquetamab-daratumumab regimens significantly improve PFS in patients with RRMM

MajesTEC-3: Teclistamab plus daratumumab maintain improved PFS and MRD negativity across high-risk multiple myeloma populations

EPCORE DLBCL-1: Epcoritamab significantly improves PFS in patients with R/R LBCL

SUCCESSOR-2: Addition of mezigdomide to Kd improves PFS and response rates in patients with RRMM

LBA4: HARMONi-6: Ivonescimab plus chemotherapy significantly improved OS versus tislelizumab plus chemotherapy in previously untreated advanced squamous NSCLC

ASCENT-03: First-line sacituzumab govitecan improves PFS versus chemotherapy in patients with advanced TNBC ineligible for PD-1/PD-L1 inhibitors

Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration